HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

HER2-positive Metastatic Breast Cancer · HER2-positive Advanced Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Institut Jules Bordet, Anderlecht, Brussels Capital, Belgium
Contact: Study coordinator (Philippe Aftimos, PhD) · philippe.aftimos@hubruxelles.be · +32 (0)2 541 32 08
CHU Charleroi - Marie Curie, Charleroi, Belgium
Contact: Study coordinator (Dana Celmare, MD) · ionela-daniela.celmare@humani.be · +31 71 922173
UZ Gent, Ghent, Belgium
Contact: Study coordinator (Hannelore Denys, MD) · Hannelore.denys@uzgent.be · +32 9 332 26 92
UZ Leuven, Leuven, Belgium
Contact: Study coordinator (Sileny Han, MD) · Sileny.han@uzleuven.be · +32 t6 34 5L 26
CHU Liège, Liège, Belgium
Contact: Study coordinator (Nadia Withofs, MD) · nwithofs@chuliege.be · +3243234362
AZ Delta, Roeselare, Belgium
Contact: Study coordinator (Kristoff Muylle, MD) · Kristoff.muylle@azdelta.be · +32 51 23 62 89
VUMC Amsterdam, Amsterdam, Netherlands
Contact: Study coordinator (Willemien Menke-van der Houven van Oordt, MD, PhD) · c.menke@amsterdamumc.nl · +31(20)4444321
UMC Groeningen, Groningen, Netherlands
Contact: Study coordinator (Michel Van Kruchten, MD) · m.van.kruchten@umcg.nl

Study leads

Martine Piccart, Md, PhD
Study Chair
Jules Bordet Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Breast Neoplasms · Breast Cancer

IsraelRecruitingPHASE1, PHASE2

Aurora, United States · Boston, United States

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Duarte, United States · Irvine, United States

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Advanced Solid Tumor · Advanced Malignant Neoplasm · Metastatic Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Irvine, United States · La Jolla, United States

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Nagoya, Japan